Webinar Video | Life Sciences Session #4: How to optimise your regulatory exclusivity rights for pharmaceutical products?

Webinar Video | Life Sciences Session #4: How to optimise your regulatory exclusivity rights for pharmaceutical products?
May 25, 2021

In the fourth online Life Sciences Session our experts, Kirian Claeyé and Laura Traest, will be focusing on regulatory exclusivity rights for pharmaceutical products, which will include data exclusivity, orphan exclusivity, SPCs and paediatric rewards. They will navigate the maze of regulatory exclusivity rights, update you on a number of significant recent developments, and discuss what is still to come. Specific topics will include:

  • The SPC manufacturing waiver
  • The CJEU’s latest case-law on SPC rights: Santen and Royalty Pharma
  • The European Commission’s review of Orphan Exclusivity and Paediatric Extensions
  • The General Court’s very recent Polpharma ruling on Data Exclusivity

Contact

  • Kirian Claeyé

    Partner

Recommended articles

August 10, 2026

Belgian Pharma Law Summer Blog Series (Part 3): the recently passed ‘Bill containing various provisions on health’

In our Belgian Pharma Law Summer Blog Series, we examine recent developments in Belgian pharmaceutical law. Whether you are looking for an informative summer read or a concise overview of the latest legal developments to catch up on after the holidays, our series has you covered. Our third and final part examines the ‘Bill containing […]

Read on
August 03, 2026

Belgian Pharma Law Summer Blog Series (Part 2): the new ‘Article 10 guidance’ on pharmaceutical promotion

In our Belgian Pharma Law Summer Blog Series, we examine recent developments in Belgian pharmaceutical law. Whether you are looking for an informative summer read or a concise overview of the latest legal developments to catch up on after the holidays, our series has you covered. Part 2 focuses on the new guidance on the […]

Read on
July 27, 2026

Belgian Pharma Law Summer Blog Series (Part 1): the Act of 30 May 2026 containing various provisions on medicinal and health products

In our Belgian Pharma Law Summer Blog Series, we examine recent developments in Belgian pharmaceutical law. Whether you are looking for an informative summer read or a concise overview of the latest legal developments to catch up on after the holidays, our series has you covered. Part 1 focuses on the Act of 30 May […]

Read on